D-0166-2020 Class III Ongoing

Recalled by AuroMedics Pharma LLC — East Windsor, NJ

FDA drug recall D-0166-2020 was initiated by AuroMedics Pharma LLC on Sep 23, 2019 and is designated Class III. Reason for recall: CGMP DEVIATIONS: One lot of Ranitidine Tablets USP, 150 mg is being recalled because some bottles were empty. The recall status is ongoing. Affected quantity: 69696 bottles.

Recall details

Product Type
Drugs
Report Date
Nov 6, 2019
Initiation Date
Sep 23, 2019
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
69696 bottles

Product description

Ranitidine Tablets USP,150 mg, 8-count bottles, Distributed by: Dolgencorp, LLC, 100 Mission Ridge, Goodlettsville, TN 37073 Made in India NDC 55910-092-79

Reason for recall

CGMP DEVIATIONS: One lot of Ranitidine Tablets USP, 150 mg is being recalled because some bottles were empty.

Distribution pattern

Nationwide within the United States

Code information

Lot #: NBSB19001DA3, Exp. date 02/2021

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0166-2020
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0166-2020. Report a data issue: hello@regdatalab.com.